Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Combidex (ferumoxtran-10) is an ultra-small iron oxide particle covered with a sugar coating.
It has been evaluated as an MRI contrast agent for use in imaging well perfused organs such
as the liver and spleen and for imaging lymph nodes. In this study, Combidex is being used to
compare the standard imaging agent, Gadolinium, in imaging brain tumors and the area adjacent
to the tumor location. Combidex may provide the ability to better see brain tumors and
inflammatory lesions on magnetic resonance imaging (MRI) scans. Combidex may be useful in its
ability to cross blood vessels into brain tumors, and because of its size and ability to get
into the area next to brain tumors, could assist in the treatment of brain tumors with other
drugs in the future.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH)